Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.

By V. Ratziu, P. Giral, S. Jacqueminet, F. Charlotte, A. Hartemann-Heurtier, L. Serfaty, P. Podevin, J. Lacorte, Carole Bernhardt, E. Bruckert and 2 more. Gastroenterology, 2008

631 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/fc82ee7089ab7b05df5a81f6fc517a92de422de3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. M. Rinella
3. K. Cusi
4. C. Day
5. A. Sanyal
6. S. Bellentani
7. G. Hotamışlıgil
8. Haiming Cao

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. A. Sanyal
4. K. Cusi
5. E. Brunt
6. C. Day
7. S. Bellentani
8. J. Lavine

In Molecular Biology

1. M. Rinella
2. G. Hotamışlıgil

Citations in the corpus

• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “Studies with rosiglitazone reported an improvement in HS, but not of necroinflammation or fibrosis.((161,162)) Rosiglitazone is no longer available in most countries, and its prescribing remains severely restricted in the United States because of controversial findings of an increase in coronary eve”
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “Five randomized controlled trials are available [203–207], which are heterogenous for drugs and dosages, duration of treatment, categories of patients included and histological outcomes [208].”
• The interaction of hepatic lipid and glucose metabolism in liver diseases. (2012, background): “In contrast, PPARc agonists prevent NAFLD progression and, more interestingly, were in some studies described to act antineoplastically [130,131].”
• Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus (2016, neutral): “1) mg/dL 109 (33) 109 (44) Mean HDL cholesterol level (SD) mmol/L 1.”
• Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. (2013, neutral): “Randomized clinical trials have shown promising results by using lifestyle modification (41, 42), vitamin E and pioglitazone (43), and rosiglitazone (44), but there is no US Food and Drug Administration–approved drug for treating NAFLD.”
• A Novel Transfer Learning Approach to Enhance Deep Neural Network Classification of Brain Functional Connectomes (2018, methodology): “Furthermore, boundary-based rigid body and FMRIB’s linear & nonlinear image registration tools (Andersson et al., 2008; Ratziu et al., 2008) were used to register functional to anatomical images.”